Adding the CDK4/6 inhibitor abemaciclib to endocrine therapy significantly improves overall survival in node-positive, ...
Overall survival outcomes in MATTERHORN trial support perioperative durvalumab plus chemotherapy as standard of care.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback